Hematopoietic cell transplantation and HIV cure: Where we are and what next?

Blood

Volumn 122, Issue 18, 2013, Pages 3111-3115

  Zou, Shimian ^a   Glynn, Simone ^a   Kuritzkes, Daniel ^b   Shah, Monica ^a   Cook, Nakela ^a   Berliner, Nancy ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; GENE TRANSFER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; SAFETY; CONFERENCE PAPER; DRUG EFFECT; HEMATOPOIETIC STEM CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; T LYMPHOCYTE; TRANSPLANTATION; VIROLOGY; DRUG EFFECTS; HIV INFECTIONS; PROCEDURES;

ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; T-LYMPHOCYTES;

EID: 84891586787     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-518316     Document Type: Article

References (37)

1. McNamara LA, Collins KL. Hematopoietic stem/ precursor cells as HIV reservoirs. Curr Opin HIV AIDS. 2011;6(1):43-48.
2. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity. 2012;37(3):377-388.
3. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7): 692-698.
4. Hütter G, Ganepola S. Eradication of HIV by transplantation of CCR5-deficient hematopoietic stem cells. ScientificWorldJournal. 2011;11:1068-1076.
5. Hoxie JA, June CH. Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med. 2012; 2(10):a007179.
6. Amado RG, Mitsuyasu RT, Rosenblatt JD, et al. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther. 2004; 15(3):251-262.
7. Macpherson JL, Boyd MP, Arndt AJ, et al. Long-term survival and concomitant gene expression of ribozyme-transduced CD41 T-lymphocytes in HIV-infected patients. J Gene Med. 2005;7(5): 552-564.
8. Mitsuyasu RT, Merigan TC, Carr A, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD341 cells. Nat Med. 2009;15(3): 285-292.
9. DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(1) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med. 2010;2(36):36ra43.
10. Hütter G, Zaia JA. Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. Clin Exp Immunol. 2011;163(3): 284-295.
11. Durand CM, Blankson JN, Siliciano RF. Developing strategies for HIV-1 eradication. Trends Immunol. 2012;33(11):554-562.
12. Burnett JC, Zaia JA, Rossi JJ. Creating genetic resistance to HIV. Curr Opin Immunol. 2012; 24(5):625-632.
13. June C, Tebas P, Stein D, et al. Induction of acquired CCR5 deficiency with zinc finger nuclease-modified autologous CD4 T Cells (SB-728-T) correlates with increases in CD4 count and effects on viral load in HIV-infected subjects. Paper presented at the 19th Conference on Retroviruses and Opportunistic Infections. March 5-8, 2012. Seattle, WA.
14. Kiem HP, Jerome KR, Deeks SG, McCune JM. Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell. 2012;10(2):137-147.
15. Durand CM, Ambinder RF. Hematopoietic stem cell transplantation in HIV-1-infected individuals: clinical challenges and the potential for viral eradication. Curr Opin Oncol. 2013;25(2): 180-186.
16. Petz LD, Redei I, Bryson Y, et al. Hematopoietic cell transplantation with cord blood for cure of HIV infections. Biol Blood Marrow Transplant. 2013; 19(3):393-397.
17. Delaney C, Ratajczak MZ, Laughlin MJ. Strategies to enhance umbilical cord blood stem cell engraftment in adult patients. Expert Rev Hematol. 2010;3(3):273-283.
18. Norkin M, Lazarus HM, Wingard JR. Umbilical cord blood graft enhancement strategies: has the time come to move these into the clinic? Bone Marrow Transplant. 2013;8(7):884-889.
19. Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011;118(24):6438-6445.
20. Van Besien K, Liu H, Jain N, Stock W, Artz A. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013; 19(5):682-691.
21. Zeidan J, Lee G, Lalezari J, et al. Central memory t cell is the critical component for sustained CD4 reconstitution in HIV subjects receiving ZFN CCR5 modified CD4 T cells (SB-728-T). Paper presented at the 20th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013. Atlanta, GA.
22. Younan PM, Polacino P, Kowalski JP, et al. Positive selection of mC46-expressing CD41 T cells and maintenance of virus specific immunity in a primate AIDS model. Blood. 2013;122(2): 179-187.
23. Voit RA, McMahon MA, Sawyer SL, Porteus MH. Generation of an HIV resistant T-cell line by targeted “stacking” of restriction factors. Mol Ther. 2013;21(4):786-795.
24. Peterson CW, Younan P, Jerome KR, Kiem HP. Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART. Gene Ther. 2013;20(7):695-702.
25. Chung J, DiGiusto DL, Rossi JJ. Combinatorial RNA-based gene therapy for the treatment of HIV/ AIDS. Expert Opin Biol Ther. 2013;13(3):437-445.
26. Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis. 2013;207(11): 1694-1702.
27. Persaud D, Gay H, Ziemniak C, et al. Functional HIV cure after very early ART of an infected infant. Paper presented at the 20th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013. Atlanta, GA.
28. McCartney M. Hype and the HIV cure. BMJ 2013; 346:f1599.
29. Luzuriaga K, Chen YH, Ziemniak C, et al. Absent HIV-specific immune responses and replication-competent HIV reservoirs in perinatally infected youth treated from infancy: towards cure. Paper presented at the 20th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013. Atlanta, GA.
30. Cohen J. HIV/AIDS. Subset of CD4 cells may hold key to reaching HIV cure. Science. 2013; 339(6125):1262.
31. Ananworanich J, Vandergeeten C, Chomchey N, et al. Early ART intervention restricts the seeding of the HIV Reservoir in long-lived central memory CD4 T cells. Paper presented at the 20th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013. Atlanta, GA.
32. Kitchen CR, Hunt P, Lee S, et al. Immunologic profile distinguishes aviremic HIV1 adults. Paper presented at the 20th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013. Atlanta, GA.
33. Durand CM, Ghiaur G, Siliciano JD, et al. HIV-1 DNA is detected in bone marrow populations containing CD41 T cells but is not found in purified CD341 hematopoietic progenitor cells in most patients on antiretroviral therapy. J Infect Dis. 2012;205(6):1014-1018.
34. Josefsson L, Eriksson S, Sinclair E, et al. Hematopoietic precursor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA. J Infect Dis. 2012;206(1):28-34.
35. Carter CC, Onafuwa-Nuga A, McNamara LA, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med. 2010;16(4):446-451.
36. Carter CC, McNamara LA, Onafuwa-Nuga A, et al. HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe. 2011; 9(3):223-234.
37. McNamara LA, Ganesh JA, Collins KL. Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-kB activation. J Virol. 2012;86(17):9337-9350.